{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:53:28Z","timestamp":1793832808226,"version":"4.6.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T00:00:00Z","timestamp":1359417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Novel intravesical therapies are needed for superficial bladder cancer that reduce the risk of infection associated with\n                            <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                            acillus\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            almette\u2013\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            u\u00e9rin (\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            ) and further destabilization of the urothelium associated with cytotoxic chemotherapy. Experimental therapies to date have included photodynamic therapy, oncolytic viruses, gene therapy (antisense oligonucleotides and silencing\n                            <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content>\n                            ), cytokine therapy, death receptor agonists (tumour\u2010necrosis\u2010factor\u2010related apoptosis\u2010inducing ligand and anti\u2010\n                            <jats:styled-content style=\"fixed-case\">DR<\/jats:styled-content>\n                            5 monoclonal antibody), naturally occurring substances (curcumin and deguelin) and human \u03b1\u2010lactalbumin made lethal to tumour cells (\n                            <jats:styled-content style=\"fixed-case\">HAMLET<\/jats:styled-content>\n                            ).\n                            <jats:styled-content style=\"fixed-case\">HAMLET<\/jats:styled-content>\n                            , a natural occurring product in milk, induces apoptosis in urothelial cancer cells but has limitations in clinical application because of its human source. A previous study in patients with bladder cancer has demonstrated that intravesical\n                            <jats:styled-content style=\"fixed-case\">HAMLET<\/jats:styled-content>\n                            (daily for 5 days before tumour resection) caused selective apoptotic tumour cell death.\n                            <jats:styled-content style=\"fixed-case\">BAMLET<\/jats:styled-content>\n                            , the bovine equivalent of\n                            <jats:styled-content style=\"fixed-case\">HAMLET<\/jats:styled-content>\n                            , is a complex of bovine \u03b1\u2010lactalbumin and oleic acid (\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            ) that has been shown\n                            <jats:italic>in vitro<\/jats:italic>\n                            to accumulate in the endolysosomal compartment of tumour cells and induce leakage of lysosomal cathepsins into the cytosol followed by activation of the pro\u2010apoptotic protein Bax.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            This is the first\n                            <jats:italic>in vivo<\/jats:italic>\n                            study to show that\n                            <jats:styled-content style=\"fixed-case\">BAMLET<\/jats:styled-content>\n                            (\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            ) induces apoptosis in urothelial cancer cells and controls the growth of high risk urothelial cancer in a syngeneic rat orthotopic model. This same bladder cancer model system has been used to test other novel therapies, including\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            , and therefore provides a relative comparison of its effectiveness with other intravesical therapies.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To investigate the efficacy of a complex of bovine \u03b1\u2010lactalbumin and oleic acid (\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            ) to kill urothelial cancer cells\n                            <jats:italic>in vitro<\/jats:italic>\n                            and inhibit tumour growth and progression in a high risk bladder tumour model.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The cytotoxicity of\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            to a large panel of urothelial cell cancer (\n                            <jats:styled-content style=\"fixed-case\">UCC<\/jats:styled-content>\n                            ) cells was tested by the\n                            <jats:styled-content style=\"fixed-case\">MTT<\/jats:styled-content>\n                            (3\u2010(4,5\u2010dimethyl\u20102\u2010thiazolyl)\u20102,5\u2010diphenyl\u20102\n                            <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                            \u2010tetrazolium bromide) assay, using\n                            <jats:styled-content style=\"fixed-case\">bLA<\/jats:styled-content>\n                            , the folded \u03b1\u2010lactalbumin without oleic acid, as a control.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The mechanism of\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            \u2010inducing cell death was evaluated by annexin\n                            <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>\n                            staining,\n                            <jats:styled-content style=\"fixed-case\">TUNEL<\/jats:styled-content>\n                            (terminal deoxynucleotidyl transferase mediated nick end labelling) assay and sub\u2010\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            <jats:sub>1<\/jats:sub>\n                            <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                            analysis.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The selective\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            cytotoxicity was examined using multicellular spheroids consisting of\n                            <jats:styled-content style=\"fixed-case\">UCC<\/jats:styled-content>\n                            and non\u2010transformed fibroblasts.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Rats bearing orthotopic tumour received intravesical instillations (twice weekly, for 3 weeks) of\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">bLA<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            or saline, starting 6 days after\n                            <jats:styled-content style=\"fixed-case\">UCC<\/jats:styled-content>\n                            (\n                            <jats:styled-content style=\"fixed-case\">AY<\/jats:styled-content>\n                            \u201027) cell inoculation. Animals were monitored for survival, toxicity and tumour growth control.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            A dose\u2010dependent\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            \u2010inducing apoptotic\u2010like cell death was shown in\n                            <jats:styled-content style=\"fixed-case\">UCC<\/jats:styled-content>\n                            cells tested, including cells refractory to classic apoptosis\u2010inducing agents, whereas b\n                            <jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content>\n                            showed little cytotoxicity.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            selectively destroyed cancer cells in spheroids.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Intravesical\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            therapy demonstrated marked reduction in tumour growth\/progression and significantly prolonged animal survival vs saline instillations (\n                            <jats:italic>\n                              <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                            <\/jats:italic>\n                            = 0.004, log\u2010rank test) and showed comparable efficacy with\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            (standard) therapy.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The findings identify\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            as a new candidate for UCC therapy and suggests that topical administration of\n                            <jats:styled-content style=\"fixed-case\">bLAC<\/jats:styled-content>\n                            alone or with\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            to prevent progression of bladder cancer warrants further exploration.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11737.x","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T10:26:22Z","timestamp":1359455182000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells\n                    <i>in vitro<\/i>\n                    and inhibits tumour growth in an orthotopic rat bladder tumour model"],"prefix":"10.1111","volume":"112","author":[{"given":"Zhengwen","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Surgery University of Alberta  Edmonton Alberta Canada"},{"name":"Department of Oncology Faculty of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Alberta  Edmonton Alberta Canada"},{"name":"Department of Oncology Faculty of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Koch","sequence":"additional","affiliation":[{"name":"NatImmune A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Alberta  Edmonton Alberta Canada"},{"name":"Department of Oncology Faculty of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcn.2001.117539"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.11.023"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.441"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38535-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.8064"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.8.4221"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2661"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22810"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032454"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-006-3607-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.04.081"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0559"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.10.148"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(03)00045-5"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690741"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000142657.62689.f6"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64000-1"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07407.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S7658"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20357"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306462200"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2001.01870.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24076"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209992"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2239"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000052388"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0374"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.008"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11737.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:04:45Z","timestamp":1761746685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11737.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,29]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11737.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11737.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,29]]},"assertion":[{"value":"2013-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}